• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Co-Diagnostics Inc.

    9/16/25 5:29:14 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care
    Get the next $CODX alert in real time by email
    424B5 1 form424b5.htm 424B5

     

    Filed Pursuant to Rule 424(b)(5)

    Registration No. 333-270628

     

    Prospectus Supplement

    (To Prospectus dated April 6, 2023)

     

     

    Up to $17,111,650

     

    Common Stock

     

    We previously entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co. (“Piper Sandler”) and Clear Street LLC (“Clear Street” and together with Piper Sandler the “Sales Agents”), pursuant to which we may offer and sell, under our prospectus supplement dated October 18, 2024 (the “Prospectus”), shares of our common stock, $0.001 par value, having an aggregate offering price of up to $17,111,650 from time to time through the Sales Agents. As of September 16, 2025, we have sold approximately $1,712,170 of shares of common stock under the Equity Distribution Agreement. This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements thereto.

     

    The purpose of this prospectus supplement is to suspend sales under the Equity Distribution Agreement and to terminate the continuous offering by us under the Prospectus effective on September 16, 2025. We will not make any sales of our common stock pursuant to the Equity Distribution Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission; however, the Equity Distribution Agreement remains in full force and effect.

     

    Our common stock is listed on The Nasdaq Capital Market under the symbol “CODX.” On September 15, 2025, the last reported sale price of our common stock on The Nasdaq Capital Market was $0.3534 per share.

     

    Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 6 of the prospectus dated April 6, 2023, the “Risk Factors” section in our most recent Annual Report on Form 10-K, which is incorporated by reference into this prospectus supplement and the Prospectus, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement and the Prospectus.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense.

     

    The date of this prospectus supplement is September 16, 2025.

     

     

     

    Get the next $CODX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CODX

    DatePrice TargetRatingAnalyst
    8/12/2022$5.00Buy → Neutral
    Sidoti
    12/29/2021$14.00Buy
    Sidoti
    11/12/2021$16.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CODX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Co-Diagnostics downgraded by Sidoti with a new price target

    Sidoti downgraded Co-Diagnostics from Buy to Neutral and set a new price target of $5.00

    8/12/22 9:07:51 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Sidoti initiated coverage on Co-Diagnostics with a new price target

    Sidoti initiated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $14.00

    12/29/21 8:45:34 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Co-Diagnostics with a new price target

    HC Wainwright & Co. reiterated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $15.00 from $16.00 previously

    11/12/21 6:13:11 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument

    CDSCO license on Form MD-5 authorizes CoSara to manufacture PCR Pro instrument in its Ranoli, India facility for sale or distribution SALT LAKE CITY, Feb. 5, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has received a license from the Central Drugs Standard Control Organization ("CDSCO") to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument for sale or distribution.

    2/5/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform

    Company and CoSara believe that ISO certification is a critical component of the regulatory requirements for clearance of new platform SALT LAKE CITY, Feb. 4, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has successfully completed the necessary audits of its quality management system ("QMS") and that its manufacturing facility located in Vadodara, India, has been granted ISO 13485:2016 certificati

    2/4/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships

    SALT LAKE CITY, Jan. 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has been strengthening its distributor base across India, recently attending and participating in two regional conferences. The events provided opportunities for CoSara to introduce its SARAGENE® diagnos

    1/12/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Murphy Edward L. was granted 57,499 shares, increasing direct ownership by 26% to 281,666 units (SEC Form 4)

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    11/24/25 5:47:27 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Brown Brian Lee was granted 134,167 shares and returned $14,253 worth of shares to the company (40,723 units at $0.35), increasing direct ownership by 18% to 599,355 units (SEC Form 4)

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    11/24/25 5:31:40 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    President Abbott Richard David returned $6,020 worth of shares to the company (17,200 units at $0.35) and was granted 56,667 shares, increasing direct ownership by 148% to 66,202 units (SEC Form 4)

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    11/24/25 5:31:21 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    SEC Filings

    View All

    SEC Form S-8 filed by Co-Diagnostics Inc.

    S-8 - Co-Diagnostics, Inc. (0001692415) (Filer)

    1/21/26 4:15:31 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Co-Diagnostics, Inc. (0001692415) (Filer)

    1/13/26 12:23:23 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Co-Diagnostics, Inc. (0001692415) (Filer)

    12/30/25 9:15:26 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Leadership Updates

    Live Leadership Updates

    View All

    Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

    SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Com

    4/4/24 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer

    SALT LAKE CITY, Aug. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Ivory Chang as the Company's Chief Regulatory Affairs Officer. Ms. Chang's in-depth regulatory affairs experience has included time spent with several notable names in the diagnostics industry, including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more. Her background has i

    8/29/23 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

    SALT LAKE CITY, Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company's new Chief Scientific Officer ("CSO"). Dr. Poritz is a Harvard University and UC San Francisco educated molecular biologist with more than 30 years of experience in the application of PCR and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection, who has also served as a reviewer for more than 30 different NIH/NIAID study sections focusing on inf

    11/1/22 9:32:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Financials

    Live finance-specific insights

    View All

    Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast

    SALT LAKE CITY, Oct. 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2025 financial results on Thursday, November 13, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

    10/31/25 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results

    SALT LAKE CITY, Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Results: Revenue of $0.2 million, which declined from $2.7 million during Q2 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the second quarter of 2025Operating expenses of approximately $8.2 million decreased by 19.1%

    8/14/25 4:01:00 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast

    SALT LAKE CITY, July 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2025 financial results on Thursday, August 14, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts.  Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

    7/31/25 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    2/13/24 5:02:32 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    2/9/22 3:43:31 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Co-Diagnostics, Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    7/12/21 8:29:19 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care